It issued the permit after a successful inspection of the production plant in Visp, southern Switzerland. At this newly approved site, Lonza can manufacture active ingredients for Covid-19 vaccines on behalf of Moderna.
Swissmedic had already approved the first Swiss plant for the production of the substance in January 2021. At this newly approved site, called “Ibex® Solutions”, one production line is fully operational and two more lines are expected to be available soon.
Companies that manufacture or distribute medicines or transplant products in Switzerland will need to have a business permit showing that they have the mandatory resources and processes to ensure and frequently monitor the quality of their products.
Lonza has a ten-year contract to supply ingredients to Moderna, adding up to one billion doses per year of Covid-19 vaccine.
SBC’s Privacy Policy provides more information about how your data is processed.
I agree to the use of my knowledge for the SWI newsletter swissinfo. ch.